(NASDAQ: BRTX) Biorestorative Therapies's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 46%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 43.09%.
Biorestorative Therapies's earnings in 2025 is -$12,670,487.On average, 4 Wall Street analysts forecast BRTX's earnings for 2025 to be -$14,757,640, with the lowest BRTX earnings forecast at -$14,439,870, and the highest BRTX earnings forecast at -$14,912,087. On average, 4 Wall Street analysts forecast BRTX's earnings for 2026 to be -$10,321,294, with the lowest BRTX earnings forecast at -$11,743,268, and the highest BRTX earnings forecast at -$8,667,650.
In 2027, BRTX is forecast to generate $7,197,745 in earnings, with the lowest earnings forecast at -$7,306,922 and the highest earnings forecast at $22,647,731.